Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AD4-HIV Envelope Vaccine Vectors in Healthy Volunteers
NCT03878121Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2019
- Primary completion
- Nov 2028
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ad4-Env150KN and Ad4-Env145NFL in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety and Immunogenicity. Started Apr 2019; status: recruiting.
02
Drugs
Ad4-Env150KNAd4-Env145NFL
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03878121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878121.